PARIS & TOKYO--(BUSINESS WIRE)--Iktos, a company specialized in Artificial Intelligence (AI) for new drug design, and Teijin Pharma Limited, the core company of the Teijin Group�s healthcare business that provides comprehensive healthcare services to improve the quality of life, today announced a strategic collaboration agreement in Artificial Intelligence for new drug design.
Under the agreement, Iktos generative modelling technology will be implemented and applied to several Teijin Pharma�s small molecule drug discovery projects to expedite the identification of potential pre-clinical candidates. Iktos and Teijin Pharma will collaborate in developing new AI technology aiming to bring further improvement and speed to the drug design process, leveraging Iktos� proprietary know-how in AI for Computer Aided Drug Design (CADD) and complementing Teijin�s research and development capabilities.
In the recent years, Iktos has emerged as one of the world leaders in AI for drug design, establishing multiple collaborations with renowned pharmaceutical companies and successfully developing the AI software platforms Makya� for new drug design and Spaya� for synthesis planning. Iktos� generative AI technology, based on deep generative models, automatically designs virtual novel molecules presenting the desirable characteristics specified by the researchers. This approach brings unprecedented efficiency in the exploration of chemical space and produces innovative molecule designs with greater freedom to operate. It is a novel solution, validated through many collaborations, to one of the key challenges in drug design: the rapid identification of molecules that simultaneously satisfy multiple parameters, such as potency, selectivity, safety, and project-specific properties.
Based on the recent drastic demographic change and increased health consciousness, Teijin Pharma is committed to providing healthcare solutions in the priority fields of bone, joint, rehabilitation, neurology, respiratory, cardiovascular and metabolic diseases. Creating innovative drugs is one of the company�s core business strategies and Teijin Pharma is now focusing on strengthening technological foundation for small molecule drugs that play major roles among the drug modalities for innovative drug discovery.
"We are thrilled and proud to announce a strategic collaboration with Teijin Pharma, a leading company that contributes to society by providing advanced healthcare solutions.�� said Yann Gaston-Math�, Co-founder and CEO of Iktos. �It is a major recognition for Iktos to be selected by Teijin Pharma as a strategic partner for implementation, development, and application of generative modeling technology for new drug design. Iktos has been a pioneer in the application of generative models for drug discovery and is recognized as a world leader in the technology space that has the potential to disrupt the way new therapeutics are designed.�� �Our ultimate objective is to expedite drug discovery and achieve time and cost efficiencies for our global collaborators by using Iktos�s proprietary AI platform and know-how. We are confident that together with our Teijin collaborators, we will be able to develop new technology to bring further speed and efficiency to drug discovery.�
�We are delighted to create innovative new small molecule drugs together with Iktos,� said Ichiro Watanabe, President of Teijin Pharma. �We provide solutions in the field of demographic change and increased health consciousness and are focusing on the launch of new drugs. Iktos� proprietary AI technology will dramatically accelerate our small molecule drug discovery. We continue to enhance patients' quality of life by providing new treatment options for diseases with high unmet needs.�
About Iktos
Incorporated in October 2016, Iktos is a start-up company specializing in the development of artificial intelligence solutions applied to chemical research, more specifically medicinal chemistry and new drug design. Iktos is developing a proprietary and innovative solution based on deep learning generative models, which enables, using existing data, the design of molecules that are optimized in silico to meet all the success criteria of a small molecule discovery project. The use of Iktos technology enables major productivity gains in upstream pharmaceutical R&D. Iktos offers its technology both as professional services and as a SaaS software platform, Makya�. Iktos is also developing Spaya�, a synthesis planning software based upon Iktos�s proprietary AI technology for retrosynthesis.
More information on: http://www.iktos.ai/
About the Teijin Group
Teijin (TSE: 3401) is a technology-driven global group offering advanced solutions in the fields of environmental value; safety, security and disaster mitigation; and demographic change and increased health consciousness. Originally established as Japan's first rayon manufacturer in 1918, Teijin has evolved into a unique enterprise encompassing three core business domains: high-performance materials including aramid, carbon fibers and composites, and also resin and plastic processing, films, polyester fibers and products converting; healthcare including pharmaceuticals and home healthcare equipment for bone/joint, respiratory and cardiovascular/metabolic diseases, nursing care and pre-symptomatic healthcare; and IT including B2B solutions for medical, corporate and public systems as well as packaged software and B2C online services for digital entertainment. Deeply committed to its stakeholders, as expressed in the brand statement �Human Chemistry, Human Solutions,� Teijin aims to be a company that supports the society of the future. The group comprises more than 170 companies and employs some 20,000 people across 20 countries worldwide. Teijin posted consolidated sales of JPY 836.5 billion (USD 7.7 billion) and total assets of JPY 1,036.4 billion (USD 9.5 billion) in the fiscal year that ended on March 31, 2021.
Please visit www.teijin.com
Contacts
Yann Gaston-Math� (CEO) � [email protected] - +33 6 30 07 99 26
Press
Corporate Communications
Teijin Limited
+81 (0)3 3506 4055
[email protected]
